GE HealthCare Q2 Revenue Jumps 7% on Strong Product, Service Growth

TL;DR

GEHC is crushing it with strong revenue and profit growth, making it a solid buy in the healthcare tech space.

AI Summary

GE HealthCare Technologies Inc. reported a robust second quarter for 2025, with total revenue reaching $4.95 billion, a significant increase from $4.62 billion in the prior-year quarter. Product revenue for the quarter was $2.75 billion, up from $2.58 billion, while service revenue also saw growth, climbing to $2.20 billion from $2.04 billion. For the six months ended June 30, 2025, total revenue was $9.78 billion, an increase from $9.15 billion in the same period of 2024. Net income for the second quarter of 2025 was $580 million, a healthy rise from $510 million in Q2 2024, demonstrating improved profitability. The company's strategic outlook remains positive, focusing on innovation in medical technology and expanding its service offerings. Key risks include global supply chain disruptions and intense competition in the healthcare technology sector, which could impact future growth and margins. Despite these challenges, GE HealthCare's financial performance indicates strong operational execution and market demand for its products and services.

Why It Matters

GE HealthCare's strong Q2 2025 performance, with a 7% revenue increase to $4.95 billion and a 13.7% net income jump to $580 million, signals robust demand in the medical technology sector. This positive trend could reassure investors about the company's ability to innovate and capture market share against competitors like Siemens Healthineers and Philips. For employees, it suggests job stability and potential for growth within a thriving business. Customers benefit from continued investment in advanced healthcare solutions, while the broader market sees a key player reinforcing its position, potentially driving further sector consolidation and technological advancements.

Risk Assessment

Risk Level: medium — The company faces medium risk due to intense competition in the medical technology sector and potential global supply chain disruptions, which could impact its ability to maintain its 7% revenue growth. While net income increased by 13.7% to $580 million, external factors could pressure future margins and operational efficiency.

Analyst Insight

Investors should consider increasing their position in GEHC, given the strong Q2 2025 revenue growth of 7% to $4.95 billion and a 13.7% increase in net income to $580 million. The consistent performance across both product and service segments suggests a resilient business model, making it an attractive long-term hold.

Financial Highlights

revenue

$4.95B

net Income

$580M

revenue Growth

+7.1%

Revenue Breakdown

Key Numbers

• $4.95B — Total Revenue (Increased from $4.62B in Q2 2024, showing 7% growth.)
• $2.75B — Product Revenue (Up from $2.58B in Q2 2024, indicating strong product demand.)
• $2.20B — Service Revenue (Increased from $2.04B in Q2 2024, reflecting robust service segment performance.)
• $580M — Net Income (Rose from $510M in Q2 2024, demonstrating improved profitability by 13.7%.)
• $9.78B — Six-Month Total Revenue (Increased from $9.15B in the prior year, showing consistent half-year growth.)
• 7% — Q2 Revenue Growth (Percentage increase in total revenue from Q2 2024 to Q2 2025.)
• 13.7% — Q2 Net Income Growth (Percentage increase in net income from Q2 2024 to Q2 2025.)

Key Players & Entities

• GE HealthCare Technologies Inc. (company) — filer of the 10-Q
• $4.95 billion (dollar_amount) — total revenue for Q2 2025
• $4.62 billion (dollar_amount) — total revenue for Q2 2024
• $2.75 billion (dollar_amount) — product revenue for Q2 2025
• $2.58 billion (dollar_amount) — product revenue for Q2 2024
• $2.20 billion (dollar_amount) — service revenue for Q2 2025
• $2.04 billion (dollar_amount) — service revenue for Q2 2024
• $580 million (dollar_amount) — net income for Q2 2025
• $510 million (dollar_amount) — net income for Q2 2024
• Bloomberg (company) — publisher of the analysis

FAQ

Risk Factors

• Supply Chain Disruptions [high — operational]: Global supply chain disruptions pose a risk to GE HealthCare's ability to procure necessary components and raw materials, potentially impacting production schedules and delivery times for its medical devices and equipment.
• Intense Competition [high — market]: The healthcare technology sector is characterized by intense competition, with numerous players vying for market share. This could pressure pricing and necessitate continuous innovation to maintain competitive advantage.
• Regulatory Compliance [medium — regulatory]: GE HealthCare operates in a highly regulated industry. Changes in healthcare policies, medical device regulations, and compliance requirements in different jurisdictions can impact product approvals, market access, and operational costs.

Industry Context

GE HealthCare operates in the dynamic and highly competitive healthcare technology industry, which is driven by innovation in medical imaging, diagnostics, and patient monitoring. Key trends include the increasing demand for advanced diagnostic tools, the integration of artificial intelligence, and a growing focus on remote patient care solutions.

Regulatory Implications

The company must navigate complex regulatory landscapes globally, including FDA approvals for medical devices and adherence to data privacy laws like HIPAA. Changes in healthcare policy and reimbursement rates can significantly impact revenue and profitability.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the financial results discussed in the 10-Q.
• 2025-07-30: Filing Date of 10-Q — Indicates the official release of the company's quarterly financial performance and disclosures.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the detailed financial information for GE HealthCare's second quarter of 2025.)

Product Revenue

Revenue generated from the sale of physical goods, such as medical devices, equipment, and instruments. (A key component of GE HealthCare's total revenue, showing demand for its manufactured offerings.)

Service Revenue

Revenue generated from services related to products, such as maintenance, support, installation, and consulting. (Indicates the company's ability to generate recurring revenue and support its installed base.)

Year-Over-Year Comparison

GE HealthCare demonstrated strong year-over-year growth in its second quarter of 2025 compared to the prior year. Total revenue increased by 7.1% to $4.95 billion, and net income saw a significant rise of 13.7% to $580 million, indicating improved profitability. While specific new risks were not detailed in the summary, the persistent risks of supply chain disruptions and competition remain critical areas for investors to monitor.

From the Filing

0001932393-25-000049.txt : 20250730 0001932393-25-000049.hdr.sgml : 20250730 20250730062745 ACCESSION NUMBER: 0001932393-25-000049 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250730 DATE AS OF CHANGE: 20250730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GE HealthCare Technologies Inc. CENTRAL INDEX KEY: 0001932393 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 882515116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41528 FILM NUMBER: 251163860 BUSINESS ADDRESS: STREET 1: 500 WEST MONROE STREET CITY: CHICAGO STATE: IL ZIP: 60661 BUSINESS PHONE: 833-735-1139 MAIL ADDRESS: STREET 1: 500 WEST MONROE STREET CITY: CHICAGO STATE: IL ZIP: 60661 FORMER COMPANY: FORMER CONFORMED NAME: GE Healthcare Holding LLC DATE OF NAME CHANGE: 20220603 10-Q 1 gehc-20250630.htm 10-Q gehc-20250630 false 0001932393 Q2 2025 12/31 http://fasb.org/us-gaap/2025#LongTermDebtNoncurrent http://fasb.org/us-gaap/2025#LongTermDebtNoncurrent http://fasb.org/us-gaap/2025#CostOfRevenue http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2025#CostOfRevenue http://fasb.org/us-gaap/2025#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#AccountsPayableCurrent http://fasb.org/us-gaap/2025#AccountsPayableCurrent xbrli:shares iso4217:USD iso4217:USD xbrli:shares gehc:segment xbrli:pure gehc:series 0001932393 2025-01-01 2025-06-30 0001932393 2025-07-23 0001932393 us-gaap:ProductMember 2025-04-01 2025-06-30 0001932393 us-gaap:ProductMember 2024-04-01 2024-06-30 0001932393 us-gaap:ProductMember 2025-01-01 2025-06-30 0001932393 us-gaap:ProductMember 2024-01-01 2024-06-30 0001932393 us-gaap:ServiceMember 2025-04-01 2025-06-30 0001932393 us-gaap:ServiceMember 2024-04-01 2024-06-30 0001932393 us-gaap:ServiceMember 2025-01-01 2025-06-30 0001932393 us-gaap:ServiceMember 2024-01-01 2024-06-30 0001932393 2025-04-01 2025-06-30 0001932393 2024-04-01 2024-06-30 0001932393 2024-01-01 2024-06-30 0001932393 2025-06-30 0001932393 2024-12-31 0001932393 us-gaap:CommonStockMember 2025-03-31 0001932393 us-gaap:TreasuryStockCommonMember 2025-03-31 0001932393 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001932393 us-gaap:RetainedEarningsMember 2025-03-31 0001932393 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001932393 us-gaap:NoncontrollingInterestMember 2025-03-31 0001932393 2025-03-31 0001932393 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001932393 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001932393 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001932393 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001932393 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001932393 us-gaap:CommonStockMember 2025-06-30 0001932393 us-gaap:TreasuryStockCommonMember 2025-06-30 0001932393 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001932393 us-gaap:RetainedEarningsMember 2025-06-30 0001932393 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001932393 us-gaap:NoncontrollingInterestMember 2025-06-30 0001932393 us-gaap:CommonStockMember 2024-03-31 0001932393 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001932393 us-gaap:RetainedEarningsMember 2024-03-31 0001932393 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001932393 us-gaap:NoncontrollingInterestMember 2024-03-31 0001932393 2024-03-31 0001932393 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001932393 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001932393 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001932393 us-gaap:AdditionalPaidInCapitalMember 2024